| Contributors: |
Huisman, Mv; Rothman, Kj; Paquette, M; Teutsch, C; Diener, Hc; Dubner, Sj; Halperin, Jl; Ma, C; Zint, K; Elsaesser, A; Bartels, Db; Lip, Gyh; Abban, D; Abdul, N; Abelson, M; Ackermann, A; Adams, F; Adams, L; Adragao, P; Ageno, W; Aggarwal, R; Agosti, S; Marin, Ja; Aguilar, F; Linares, Jaa; Aguinaga, L; Ahmad, Z; Ainsworth, P; Al Ghalayini, K; Al Ismail, S; Alasfar, A; Alawwa, A; Al-Dallow, R; Alderson, L; Alexopoulos, D; Ali, A; Ali, M; Aliyar, P; Al-Joundi, T; Al Mahameed, S; Almassi, H; Almuti, K; Al-Obaidi, M; Alshehri, M; Altmann, U; Alves, Ar; Al-Zoebi, A; Amara, W; Amelot, M; Amjadi, N; Ammirati, F; Andrawis, N; Angoulvant, D; Annoni, G; Ansalone, G; Antonescu, Sa; Ariani, M; Arias, Jc; Armero, S; Arora, R; Arora, C; Ashcraft, W; Aslam, M; Astesiano, A; Audouin, P; Augenbraun, C; Aydin, S; Azar, R; Azim, A; Aziz, S; Backes, Lm; Baig, M; Bains, S; Bakbak, A; Baker, S; Bakhtiar, K; Bala, R; Banayan, J; Bandh, S; Bando, S; Banerjee, S; Bank, A; Barbarash, O; Baron, G; Barr, C; Barrera, C; Barton, J; Kes, Vb; Baula, G; Bayeh, H; Bazargani, N; Behrens, S; Bell, A; Benezet-Mazuecos, J; Benhalima, B; Berdague, P; Van Den Berg, Bj; Van Bergen, Pfmm; Berngard, E; Bernstein, R |
| Description: |
BACKGROUND GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non-vitamin K antagonist oral anticoagulant (NOAC), became available. OBJECTIVES This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. METHODS During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients' baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. RESULTS Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA(2)DS(2)-VASc [ Congestive heart failure, Hypertension, Age >= 75 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score >= 2; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet ... |